PSWR yields 2000000.00% · ABBV yields 3.06%● Live data
📍 PSWR pulled ahead of the other in Year 1
Combined, PSWR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PSWR + ABBV for your $10,000?
Prism Software Corporation provides a suite of print and document management software products primarily in the United States. The company's products include DocAudit for protecting confidential information by creating a secure audit record of copy, print, scan, fax, and email activities; DocForm, a personalized communication solution for production printing and cross-channel messaging for midsize-to-enterprise organizations; DocQueue, a secure document release and print queue management solution for local and remote print jobs; and DocRecord, which is an enterprise document and content management system that is designed for midsize-to-small organizations. Its products also comprise DocSystem, an automated document processing and workflow solution that enables automatic and instant electronic routing of eDocuments; GroupPoint, a community-based workflow and collaboration solution with intuitive document composition and editing; PrintPath, which is a print-and-copy tracking and cost recovery application; ScanPath, a solution for converting scanned documents to editable word, excel, pdf and file formats; and ScanPath Desktop, an automated and advanced desktop document processing solution. The company serves the variable data printing, document output management, and legacy data printing and conversion markets. Prism Software Corporation was founded in 1992 and is based in Irvine, California.
Full PSWR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.